Search Results
Oct 06, 2025, 08:00 ET Alcresta Therapeutics Expands Executive Leadership to Drive Strategic Initiatives
Ian Vawter joins as Chief Financial Officer WALTHAM, Mass., Oct. 6, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing
More news about: Alcresta Therapeutics, Inc.
Oct 06, 2025, 08:00 ET New research shows private credit fund structuring evolution driven by investor demand for liquidity, customization, rated notes and co-investment
savers? Retailization has taken place mostly at the level of HNW and semi-professional investors, rather than mass retail. Retail investors can access the asset class typically via parallel vehicles, though managers have established partnerships with wealth management
More news about: Dechert LLP
Oct 06, 2025, 07:00 ET Data from First-in-Human Clinical Studies of the Hyalex Freestyle Knee Implant to be Presented at the ICRS Congress 2025
LEXINGTON, Mass., Oct. 6, 2025 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing joint preservation technologies based on the transformative HYALEX Hydrosurf™
More news about: Hyalex Orthopaedics
Oct 06, 2025, 07:00 ET Dr. Rod J. Rohrich Ranked Number 1 in the United States for Eyelid Surgery by Newsweek
Professor and Chair of the Department of Plastic Surgery at UT Southwestern Medical Center. He trained at Baylor, the University of Michigan, Harvard/Mass General, and Oxford. A leader in the field, Dr. Rohrich chairs the Dallas Rhinoplasty Meeting, founded the Dallas Cosmetic Surgery
More news about: Dr. Rod J. Rohrich
Oct 06, 2025, 02:11 ET FDA Lifts Clinical Hold on NUZ-001
value. Next Steps: With IND now active, Neurizon anticipates Mass General Hospital (MGH) filing a protocol amendment to their IND for the HEALEY ALS Platform Trial to incorporate our specific protocol regimen early
More news about: Neurizon Therapeutics Limited
Oct 06, 2025, 02:06 ET FDA Lifts Clinical Hold on NUZ-001
value. Next Steps: With IND now active, Neurizon anticipates Mass General Hospital (MGH) filing a protocol amendment to their IND for the HEALEY ALS Platform Trial to incorporate our specific protocol regimen early
More news about: Neurizon Therapeutics Limited